Cochrane Review Group
Eyes and Vision
171 systematic reviews in Eyes and Vision ask 2,112 questions. 27.8% have no studies to answer them, 21.1% rest on very low certainty evidence and 20.2% reach moderate or high certainty.
Reviews
171
Questions
2,112
current versions
No studies
27.8%
Moderate or high
20.2%
No studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
LipiFlow vs basic warm compresses Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | NR | Very low |
LipiFlow vs thermostatic devices Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | 4 studies · 445 participants | Very low |
LipiFlow vs basic warm compresses Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | SMD 1.31 | 2 studies · 76 participants | Very low |
LipiFlow vs basic warm compresses Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | 1 study · 46 participants | Very low |
LipiFlow vs thermostatic devices Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | NR | Very low |
Face‐down positioning vs other positioning Proportion of eyes with retinal displacement at 6 months or later (RR < 1 favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | RR 0.73 [0.54, 0.99] | 1 study · 239 participants | Very low |
Face‐down positioning vs other positioning Mean change in logMAR or Snellen visual acuity from baseline to 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 56 participants | Very low |
Face‐down positioning vs other positioning Mean objective distortion score at 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | MD 1.8 | 1 study · 219 participants | Very low |
Face‐down positioning vs other positioning Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 217 participants | Very low |
Face‐down positioning vs other positioning Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 262 participants | Very low |
Face‐down positioning vs other positioning Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | NR | No studies |
Lutein with or without zeaxanthin vs placebo Adverse effects · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | OR 1.06 | NR | Very low |
Reviews 171
LipiFlow for the treatment of dry eye disease
CochraneSoF table
10 questions
Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal detachments
CochraneSoF table
6 questions
Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration
CochraneSoF table
28 questions
Antibiotics versus placebo for acute bacterial conjunctivitis
CochraneSoF table
7 questions
Interventions for acute non‐arteritic central retinal artery occlusion
CochraneSoF table
3 questions
Interventions for infantile esotropia
CochraneSoF table
6 questions
Medical interventions for traumatic hyphema
CochraneSoF table
39 questions
Blood pressure control for diabetic retinopathy
CochraneSoF table
7 questions
Botulinum toxin for the treatment of strabismus
CochraneSoF table
6 questions
Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis
CochraneSoF table
37 questions
Anti‐vascular endothelial growth factor for neovascular glaucoma
CochraneSoF table
6 questions
Anti‐vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy
CochraneSoF table
7 questions
Face‐down positioning or posturing after macular hole surgery
CochraneSoF table
4 questions
Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy
CochraneSoF table
8 questions
Complement inhibitors for age‐related macular degeneration
CochraneSoF table
28 questions
Corticosteroid implants for chronic non‐infectious uveitis
CochraneSoF table
14 questions
Device‐modified trabeculectomy for glaucoma
CochraneSoF table
7 questions
Laser‐assisted cataract surgery versus standard ultrasound phacoemulsification cataract surgery
CochraneSoF table
7 questions
Telerehabilitation for people with low vision
CochraneSoF table
5 questions
Iridotomy to slow progression of visual field loss in angle‐closure glaucoma
CochraneSoF table
7 questions
Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants with presbyopia
CochraneSoF table
7 questions
Blue‐light filtering spectacle lenses for visual performance, sleep, and macular health in adults
CochraneSoF table
7 questions
Fenofibrate for diabetic retinopathy
CochraneSoF table
7 questions
Interventions for myopia control in children: a living systematic review and network meta‐analysis
CochraneSoF table
39 questions
Silicone hydrogel versus hydrogel soft contact lenses for differences in patient‐reported eye comfort and safety
CochraneSoF table
7 questions